PHARMACY

Pfizer supports World Malaria Day with new campaign

BY Alaric DeArment

NEW YORK A U.S. drug company is marking World Malaria Day with a campaign to commemorate the work done to fight a disease that kills at least 880,000 people per year.

Pfizer announced Friday that it would commemorate the work that its employees do with a “Counting Malaria Out” campaign coinciding with World Malaria Day on Saturday.

 

Pfizer’s portfolio of malaria drugs includes Camoquin-Plus (artesunate-amodiaquine), which treats uncomplicated malaria, and Metakelfin (sulphalene-pyramethamine), for pregnant women with the disease.

“Although there have been significant advancements over the last five years, including new money, medicines and increased energy towards fighting the disease, critical gaps still exist in treating specific population groups and delivering medicines,” Pfizer emerging markets business unit SVP medical and development Sam Azoulay said. “Pfizer has created a new malaria platform to address these gaps through its portfolio of products, scientific efforts and licensing activities.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Eli Lilly & Co. granted preliminary injunction against Teva

BY Alaric DeArment

INDIANAPOLIS A U.S. District Court has granted drug maker Eli Lilly & Co. a preliminary injunction preventing the launch of a generic version of one of its drugs, Lilly announced Wednesday.

The company said the U.S. District Court for the Southern District of Indiana issued the injunction to prevent Teva Pharmaceuticals’ launch of raloxifene hydrochloride tablets, a generic version of Lilly’s osteoporosis drug Evista.

Patents on Evista begin expiring in 2012. The drug had sales of $700.5 million in 2008, according to Lilly financial data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

DFB Pharmaceuticals appoints new VP business development, corporate finance

BY Alaric DeArment

FORT WORTH, Texas DFB Pharmaceuticals announced Thursday that it promoted Maxwell Lea to VP business development and corporate finance.

Lea most recently served as director of corporate development and finance for the company. As vice president, he will manage DFB’s capital raising and financing activities, business development initiatives and strategic planning. He will also be responsible for business development efforts for DFB affiliate Healthpoint.

“Since joining DFB in 2002, Maxwell has positively impacted every level of our company and its affiliate businesses,” CFO Michael Patterson said. “I can say without reservation that our companies have excelled due to his success.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?